Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)3'-spiro-5''-(4''-amino-1'', 2''- oxathiole-2'',2''-dioxide] (TSAO)

Molecular Pharmacology

Volumn 50, Issue 5, 1996, Pages 1057-1064

  Arion, Dominique ^a   Fletcher, Ronald S ^a   Borkow, Gadi ^a   Camarasa, María José ^b   Balzarini, Jan ^c   Dmitrienko, Gary I ^d   Parniak, Michael A ^a  

^a MCGILL UNIVERSITY   (Canada)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d UNIVERSITY OF WATERLOO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2',5' BIS O (TERT BUTYLDIMETHYLSILYL) BETA RIBOFURANOSYL] 3' SPIRO 5'' (4'' AMINO 1'', 2'' OXATHIOLE 2'',2'' DIOXIDE) 3 ETHYLTHYMINE; 9 AMINONEVIRAPINE; DNA POLYMERASE; NEVIRAPINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION;

ANTIVIRAL AGENTS; BENZODIAZEPINES; BINDING SITES; DNA-DIRECTED DNA POLYMERASE; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; KINETICS; PHOTOCHEMISTRY; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE;

EID: 0029804757     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Mitsuya, H., K. J. Weinhold, P. A. Furman, M. H. St. Clair, S. N. Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder. 3′-Azido-3′deoxythymidine (BWA509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 82:7096-7100 (1985).
2. Yarchoan, R., H. Mitsuya, R. V. Thomas, J. M. Pluda, N. R. Hartman, C-F. Perno, K. S. Marczyk, J-P. Allain, D. G. Johns, and S. Broder. In vitro activity against HIV and favorable toxicity profile of 2′3′-dideoxyinosine. Science (Washington D. C.) 245:412-415 (1989).
3. Huang, P., D. Farquhar, and W. Plunkett. Selective action of 3′-azido-3′-dideoxythymidine 5′-triphosphate on viral reverse transcriptase and human DNA polymerases. J. Biol. Chem. 265:11914-11918 (1990).
4. Soudeyns, H., X-J. Yao, Q. Gao, B. Belleau, J-L. Kraus, N. Nguyen-Ba, B. Spira, and M. A. Wainberg. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob. Agents Chemother. 35:1386-1390 (1991).
5. Schinazi, R. F., C. K. Chu, A. Peck, A. McMillan, R. Mathis, D. Cannon, L-S. Jeong, J. W. Beach, W-B. Choí, S. Yeola, and D. C. Liotta. Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob. Agents Chemother. 36:672-676 (1992).
6. Furman, P. A., J. A. Fyfe, M. H. St. Clair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. N. Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, and D. W. Barry. Mode of inhibition of the human T-cell lymphotropic virus III by 3′-azido-3′-dideoxythymidine. Proc. Natl. Acad. Sci. USA 83:8333-8337 (1986).
7. Gu, Z., R. S. Fletcher, E. J. Arts, M. A. Wainberg, and M. A. Parniak. The K65R mutant reverse transcriptase of HIV-1 cross resistant to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-3′-thiacytidine, and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J. Biol. Chem. 269:28118-28122 (1994).
8. Gu, Z., E. J. Arts, M. A. Parniak, and M. A. Wainberg. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2′,3′-dideoxycytidine 5′-triphosphate and other drugs. Proc. Natl. Acad. Sci. USA 92:2760-2764 (1995).
9. Merluzzi, V. J., K. D. Hargrave, M. Labadia, K. Grozinger, M. T. Skoog, J. C. Wu, C-K. Shih, K. Eckner, S. Hattox, J. Adams, A. S. Rosehthal, R. Faanes, R. J. Eckner, R. A. Koup, and J. L. Sullivan. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science (Washington D. C.) 250:1411-1413 (1990).
10. Kopp, E. B., J. J. Miglietta, A. G. Shrutkowski, C-K. Shih, P. M. Grob, and M. T. Skoog. Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template. Nucleic Acids Res. 19:3035-3039 (1991).
11. Pauwels, R., K. Andries, J. Desmyter, D. Schols, M. J. Kukla, H. J. Breslin, A. Raeymaeckers, J. Van Gelder, R. Woestenborghs, J. Heykants, K. Schellekens, M. A. Janssen, E. De Clercq, and P. A. J. Janssen. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (Lond.) 343:470-474 (1990).
12. Goldman, M. E., J. H. Nunberg, J. A. O'Brien, J. C. Quintero, J. M. Schlief, K. F. Freund, S. L. Gaul, W. S. Saari, J. S. Wai, J. M. Hoffman, P. S. Anderson, D. J. Hupe, E. A. Emini, and A. M. Stern. Pyridone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. USA 88:6863-6867 (1991).
13. Bader, J. P., J. B. McMahon, R. J. Schultz, V. L. Narayanan, J. B. Pierce, O. S. Weislow, C. F. Midelfort, S. F. Stinson, and M. R. Boyd. Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc. Natl. Acad. Sci. USA 88:6740-6744 (1991).
14. Fletcher, R. S., K. Syed, S. Mithani, G. I. Dmitrienko, and M. A. Parniak. Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme. Biochemistry 34:4346-4353 (1995).
15. Fletcher, R. S., D. Arion, G. Borkow, M. A. Wainberg, G. I. Dmitrienko, and M. A. Parniak. Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds. Biochemistry 34:10106-10112 (1995).
16. Wu, J. C., T. C. Warren, J. Adams, J. Proudfoot, J. Skiles, P. Raghavan, C. Perry, I. Potocki, P. R. Farina, and P. M. Grob. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry 30:2022-2026 (1991).
17. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (Washington D. C.) 256:1783-1790 (1992).
18. Smerdon, S. J., J. Jäger, L. A. Kohlstaedt, A. J. Chirino, J. M. Friedman, P. A. Rice, and T. A. Steitz. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 91:3911-3915 (1994).
19. Ding, J., K. Das, H. Moereels, L. Koymans, K. Andries, P. A. J. Janssen, S. H. Hughes, and E. Arnold. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat. Struct. Biol. 2:407-415 (1995).
20. Ren, J., R. Esnouf, E. German, D. Somers, C. Ross, I. Kirby, J. Keeling, G. Darby, Y. Jones, D. Stuart, and D. Stammers. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Nat. Struct. Biol. 2:293-302 (1995).
21. Balzarini, J., M-J. Pérez-Pérez, A. San-Félix, M-J. Camarasa, I. C. Bathurst, P. J. Barr, and E. De Clercq. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-o-(terf-butyldimethylsilyl)-b-D-ribofuranosyl]-3′- spiro-5″-(4″-amino-1″, 2″-oxathiole-2″, 2″-dioxide)thymine (TSAO-T). J. Biol. Chem. 267:11831-11838 (1992).
22. Balzarini, J., M-J. Pérez-Pérez, A. San-Félix, D. Schols, C-F. Perno, A-M. Vandamme, M-J. Camarasa, and E. De Clercq. 2′,5′-bis-o-(tertbutyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″, 2″-oxathiole-2″, 2″-dioxide) pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl. Acad. Sci. USA 89:4392-4396 (1992).
23. Balzarini, J., A. Karlsson, A-M. Vandamme, M-J. Pérez-Pérez, H. Zhang, L. Vrang, B. Oberg, K. Backbro, T. Unge, A. San-Felix, S. Velázquez, M-J. Camarasa, and E. De Clercq. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis-o-(tert-butyldimethylsilyl)ribofuranosyl]-3′-spiro- 5″-(4″- amino-1″, 2″-oxathiole-2″, 2″-dioxide)]-b-D- pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 90:6952-6956 (1993).
24. Boyer, P. L., J. Ding. E. Arnold, and S. H. Hughes. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:1909-1914 (1994).
25. Jonckheere, H., J-M. Taymans, J. Balzarini, S. Velázquez, M-J. Camarasa, J. Desmyter, E. De Clercq, and J. Anné. Resistance of HIV-1 reverse transcriptase against [2′,5′-bis-o-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″, 2″-oxathiole-2″, 2″-dioxide)] (TSAO). J. Biol. Chem. 269:25255-25258 (1994).
26. Hargrave, K. D., J. R. Proudfoot, K. G. Grozinger, E. Cullen, S. R. Kapadia, U. R. Patel, V. U. Fuchs, S. C. Maudlin, J. Vitous, M. L. Behnke, J. M. Klunder, K. Pal, J. W. Skiles, D. W. McNeil, J. M. Rose, G. C. Chow, M. T. Skoog, J. C. Wu, G. Schmidt, W. W. Engel, W. G. Eberlein, T. D. Saboe, S. J. Campbell, A. S. Rosenthal, and J. Adams. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridobenzodiazepinones. J. Med. Chem. 34:2231-2241 (1991).
27. Grob, P. M., J. C. Wu, K. A. Cohen, R. H. Ingraham, C-K. Shih, K. D. Hargrave, T. L. McTague, and V. J. Merluzzi. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug. AIDS Res. Hum. Retroviruses 8:145-152 (1992).
28. Pérez-Pérez, M-J., A. San-Félix, J. Balzarini, E. De Clercq, and M-J. Camarasa. TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of [1-[2′,5′-bis-o-(tert-butyldimethylsilyl)-b-D-ribofuranosyl]- 3′-spiro-5″-(4″-amino-1″, 2″-oxathiole-2″, 2″-dioxide) pyrimidine and pyrimidine-modified nucleosides. J. Med. Chem. 35:2988-2995 (1992).
29. Lys-3 as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template switching reaction. J. Biol. Chem. 269:14672-14680 (1994).
30. Fletcher, R. S., G. Holleschak, E. Nagy, D. Arion, G. Borkow, Z. Gu, M. A. Wainberg, and M. A. Parniak. Single-step purification of recombinant wild type and mutant HIV-1 reverse transcriptase. Protein Expr. Purif. 7:27-32 (1996).
31. Chou, T.-C., and P. Talalay. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55 (1984).
32. Beard, W. A., and S. H. Wilson. Kinetic analysis of template-primer interactions with recombinant forms of HIV-1 reverse transcriptase. Biochemistry 32:9745-9753 (1993).
33. Tantillo, C., J. Ding, A. Jacobo-Molina, R. G. Nanni, P. L. Boyer, S. H. Hughes, R. Pauwels, K. Andries, P. A. J. Janssen, and E. Arnold. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HTV-1 reverse transcriptase. Implications for mechanism of drug inhibition and resistance. J. Mol. Biol. 243:369-387 (1994).
34. Huber, E. H., J. M. McCoy, J. S. Seerah, and C. C. Richardson. Human immunodeficiency virus 1 reverse transcriptase. Template binding, processivity, strand displacement synthesis, and template switching. J. Biol. Chem. 264:4669-4678 (1989).
35. Williams, K. J., L. A. Loeb, and M. Fry. Synthesis of DNA by human immunodeficiency virus reverse transcriptase is preferentially blocked at template oligo(deoxyadenosine) tracts. J. Biol. Chem. 265:18682-18689 (1990).
36. Abbotts, J., K. Bebenek, T. A Kunkel, and S. H. Wilson. Mechanism of HIV-1 reverse transcriptase. Termination of processive synthesis on a natural DNA template is influenced by the sequence of the template-primer stem. J. Biol. Chem. 268:10312-10323 (1993).
37. Klarmann, G. J., C. A. Schauber, and B. D. Preston. Template-directed pausing of DNA synthesis by HIV-1 reverse transcriptase during polymerzation of HIV-1 sequences in vitro. J. Biol. Chem. 268:9793-9802 (1993)
38. Reardon, J. E., E. S. Furfine, and N. Cheng. Human immunodeficiency virus reverse transcriptase. Effect of primer length on template-primer binding. J. Biol. Chem. 266:14128-14134 (1991).
39. Kati, W. M., K. A. Johnson, L. F. Jerva, and K. S. Anderson. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 267:25988-25997 (1992).
40. Olsen, D. B., S. S. Carroll, J. C. Culberson, J. A. Shafer, and L. C. Kuo. Effect of template secondary structure on the inhibition of HIV-1 reverse transcriptase by a pyridinone non-nucleoside inhibitor. Nucleic Acids Res. 22:1437-1443 (1994).